All News
Filter News
Found 41,803 articles
-
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
4/17/2024
Windtree Therapeutics, Inc. today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided key business updates.
-
Delve Bio presents study showing utility of metagenomic next generation sequencing (mNGS) in diagnosing neurological infections
4/17/2024
Delve Bio in collaboration with the University of California, San Francisco (UCSF), today announced data on the use of mNGS for the diagnosis of infectious causes of meningitis and/or encephalitis in real-world clinical settings.
-
Sensorium Therapeutics Appoints Sam Rasty as Chief Business Officer
4/17/2024
Sensorium Therapeutics today announced the appointment of Sam Rasty, Ph.D., as Chief Business Officer.
-
Despite the strong performance of its cancer portfolio, Johnson & Johnson on Tuesday reported Stelara sales of $2.45 billion in the first quarter of 2024, falling short of Wall Street expectations of $2.6 billion.
-
Viral Vector and Plasmid DNA Manufacturing Market Size, CAGR, Share, Report 2024 to 2033
4/16/2024
According to Vision Research Reports, the global viral vector and plasmid DNA manufacturing market size was estimated at around USD 5.37 billion
-
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
4/16/2024
Calidi Biotherapeutics, Inc. today announced the pricing of its “reasonable best efforts” public offering of 15,197,500 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A Common Warrants.
-
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
4/16/2024
Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million.
-
CSafe Elevates Cell and Gene Therapy Transport with Reusable Cryogenic Solution
4/16/2024
CSafe , an active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, proudly announces the launch of a new line of cryogenic multi-use dewars for the cell and gene therapy market.
-
FDA Roundup: April 16, 2024
4/16/2024
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.
-
Cardiawave appoints Olivier Pierron as its Chief Executive Officer
4/16/2024
Cardiawave SA, a French Medtech company that has developed an innovative Non-Invasive Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, is delighted to announce the appointment of Olivier Pierron as its new Chief Executive Officer.
-
GeneVentiv Therapeutics Awarded $2.5 Million SBIR Grant to Advance Gene Therapy for All Hemophilias, with or without Inhibitors
4/16/2024
GeneVentiv Therapeutics, developer of GENV-HEM for all hemophilias, announced it has been awarded a Direct to Phase II Small Business Innovation Research grant for approximately $2,500,000 from the National Heart Lung Blood Institute at the National Institutes of Health.
-
Experts are hopeful that objective biomarker measures for amyotrophic lateral sclerosis, such as the ones being developed by EverythingALS, will lead to more targeted, effective treatments.
-
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
4/15/2024
Invivyd, Inc. announced that the U.S. Centers for Medicare & Medicaid Services has granted a Healthcare Common Procedure Coding System Q code covering product reimbursement for PEMGARDA.
-
Pharmacogenomics Market Size is Forecasted to Worth USD 35.67 Billion by 2032
4/15/2024
The global pharmacogenomics market size was reached at USD 15 billion in 2022 and is forecasted to be worth over USD 35.67 billion by 2032 with a CAGR of 9.1% from 2023 to 2032.
-
Kraig Biocraft Laboratories Announces Successful Launch of Spring Production Trials in Southeast Asia for Spider Silk
4/15/2024
Kraig Biocraft Laboratories, Inc., announces that the spring production trials for the new BAM-1 hybrid have begun and are well on track to meet the Company's expectations and timeline.
-
First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial
4/15/2024
Actinogen Medical Limited announces that the first patient has been randomized and treated in the XanaMIA phase 2b clinical trial in patients with biomarker-positive mild to moderate Alzheimer's disease (AD).
-
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4/15/2024
Aileron Therapeutics, Inc. (“Aileron”, the “Company”, “we”, “our” or “us”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.
-
This week’s American Association for Cancer Research annual meeting drove home the importance of antibody-drug conjugates as an emerging class of potential anti-cancer therapeutics.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
【2024 AACR Late Breaking Research】TransThera announces clinical data of tinengotinib to treat patients with advanced solid tumors harboring actionable FGFR1-3 alterations
4/12/2024
TransThera Sciences, a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, announced the poster presentation at the 2024 American Association for Cancer Research to discuss the latest breaking research of tinengotinib for patients with advanced solid tumors harboring actionable FGFR1-3 alterations.